long acting CNP (BMN 333)
/ BioMarin
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 03, 2026
ASPEN: A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
(clinicaltrials.gov)
- P2/3 | N=160 | Not yet recruiting | Sponsor: BioMarin Pharmaceutical
New P2/3 trial • Genetic Disorders
1 to 1
Of
1
Go to page
1